Letter to the Editor
Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders

https://doi.org/10.1016/j.jaci.2017.10.039Get rights and content

First page preview

First page preview
Click to open first page preview

References (9)

There are more references available in the full text version of this article.

Cited by (101)

  • Cell death

    2024, Cell
  • A20 Haploinsufficiency: A Systematic Review of 177 Cases

    2024, Journal of Investigative Dermatology
  • Monogenic Systemic Autoinflammatory Diseases

    2022, Encyclopedia of Infection and Immunity
View all citing articles on Scopus

This work was supported by Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (grant nos. 17933688 and 17933299).

Disclosure of potential conflict of interest: H. Ohnishi has received Health and Labour Sciences Research Grants. K. Imai has received a grant from the Japanese Ministry of Health, Labour and Welfare and Sony, Inc; has consultant arrangements with CSL Behring KK and Novartis Pharma KK; and has received payment for lectures from CLS Behring and the Japan Blood Products Organization. R. Nishikomori has received payment for lectures from Novartis, Inc. S. Ito has received grants from Astellas Pharma, Inc, Pfizer Japan, Inc, AbbVie GK, Eisai Co Ltd, Sumitomo Dainipponn Pharma Co Ltd, Merck Sharp & Dohme, CSL Behring, and Kyowa Hakko Kirin Co Ltd and has received payment for lectures from Astellas Pharma, Inc, Pfizer Japan, Inc, Sanofi, AbbVie GK, Eisai Co Ltd, Asahi Kasei Parma Corporation, Sumitomo Dainipponn Pharma Co Ltd, Mitsubishi Tanabe Pharma Corporation, and Zenyaku Kogyo Co Ltd. T. Heike has received a grant from the Ministry of Health, Labour, and Welfare. O. Ohara has received a grant from the Jeffrey Modell Foundation. T. Morio has received consultant fees from Novartis, Chugai Pharmaceutical, and Teijin Pharma; has received grants from Asteras, CSL Behring, and Pfizer; and has received payment for lectures from Asteras, AbbVie, CSL Behring, Dainippon Sumitomo Pharmaceutical, JBPO, Tanabe Mitsubishi Pharmaceutical, and Teijin Pharma. T. Fukao has received grants from the Japan Agency for Medical Research and Development, Health and Labour Sciences Research Grants, Sanofi, Pfizer Japan, Inc, Chugai Pharm, Astellas, and Eli Lilly Japan KK. The rest of the authors declare that they have no relevant conflicts of interest.

These authors contributed equally to this work.

View full text